MiNK Therapeutics, Inc. (INKT)

0.9799 -0.0001 (-0.01%) As of 12:00PM EDT. Market open.

MiNK Therapeutics, Inc.

149 Fifth Avenue
Suite 500
New York, NY 10010
United States
212 994 8250
https://minktherapeutics.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 31

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Garo H. Armen Ph.D.	Executive Chairman	N/A	N/A	1953
Dr. Jennifer S. Buell Ph.D.	President, CEO & Director	916.75k	N/A	1976
Dr. Marcus Antonius van Dijk Ph.D.	Chief Scientific Officer	458.28k	N/A	1962
Ms. Christine M. Klaskin	Treasurer	29.62k	N/A	1966
Joy Zhou Ph.D.	Vice President & Head of CMC	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.

Corporate governance

MiNK Therapeutics, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.